Arcellx, Inc. (NASDAQ:ACLX - Get Free Report) Director Kavita Patel sold 1,500 shares of the firm's stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $91.88, for a total value of $137,820.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Kavita Patel also recently made the following trade(s):
- On Friday, November 8th, Kavita Patel sold 33,763 shares of Arcellx stock. The stock was sold at an average price of $104.14, for a total transaction of $3,516,078.82.
- On Monday, November 11th, Kavita Patel sold 15,238 shares of Arcellx stock. The shares were sold at an average price of $105.92, for a total transaction of $1,614,008.96.
- On Tuesday, October 22nd, Kavita Patel sold 1,500 shares of Arcellx stock. The stock was sold at an average price of $89.69, for a total transaction of $134,535.00.
- On Tuesday, September 10th, Kavita Patel sold 1,500 shares of Arcellx stock. The stock was sold at an average price of $74.41, for a total value of $111,615.00.
Arcellx Price Performance
Shares of Arcellx stock opened at $86.42 on Friday. The firm has a market cap of $4.67 billion, a price-to-earnings ratio of -121.72 and a beta of 0.25. Arcellx, Inc. has a one year low of $46.42 and a one year high of $107.37. The stock's 50-day moving average is $88.42 and its 200-day moving average is $71.12.
[PDF] The Opportunity in Gold
From DTI | Ad
Commodities expert, Geof Smith, insists that the supercycle on gold is just getting warmed up.
In fact, even though gold looks like this since he initially called a major bull run 11 months ago…
He’s still predicting it will be the TOP trade of 2025.
His free eBook explains why
You see, the last time gold launched into a supercycle like this it surged 536%
The time before that was over 1,000%...
That’s why Geof released this urgent guide to help you.
Most people think they’ve missed out, but he thinks we’re at the very beginning of what could be the largest gold rally of our lifetimes.
But, believe it or not, Geof doesn’t think you should just buy and hold precious metals.
He’ll share more about his approach inside the eBook and it might surprise you.
Tap here to read it
Arcellx (NASDAQ:ACLX - Get Free Report) last announced its earnings results on Thursday, November 7th. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.06. Arcellx had a negative net margin of 25.94% and a negative return on equity of 8.28%. The business had revenue of $26.03 million during the quarter, compared to analysts' expectations of $35.21 million. On average, equities analysts expect that Arcellx, Inc. will post -1.49 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of ACLX. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Arcellx by 21.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,944 shares of the company's stock valued at $161,000 after purchasing an additional 347 shares during the period. Quest Partners LLC acquired a new position in Arcellx in the 2nd quarter valued at about $27,000. National Bank of Canada FI lifted its position in Arcellx by 50.0% during the second quarter. National Bank of Canada FI now owns 1,500 shares of the company's stock worth $80,000 after acquiring an additional 500 shares during the last quarter. High Net Worth Advisory Group LLC lifted its position in Arcellx by 6.3% during the third quarter. High Net Worth Advisory Group LLC now owns 8,500 shares of the company's stock worth $710,000 after acquiring an additional 500 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its holdings in shares of Arcellx by 1.4% during the second quarter. Principal Financial Group Inc. now owns 37,352 shares of the company's stock worth $2,061,000 after acquiring an additional 517 shares during the period. Institutional investors own 96.03% of the company's stock.
Analyst Upgrades and Downgrades
A number of equities analysts have weighed in on ACLX shares. Redburn Atlantic started coverage on shares of Arcellx in a research note on Tuesday, October 8th. They issued a "buy" rating and a $109.00 target price for the company. Barclays raised Arcellx to a "strong-buy" rating in a report on Friday, November 29th. Truist Financial lifted their target price on Arcellx from $87.00 to $136.00 and gave the company a "buy" rating in a research note on Tuesday, November 12th. Robert W. Baird upped their price target on Arcellx from $77.00 to $106.00 and gave the company an "outperform" rating in a research note on Wednesday, November 6th. Finally, Bank of America raised their price target on Arcellx from $84.00 to $100.00 and gave the company a "buy" rating in a report on Wednesday, November 6th. Twelve investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $103.08.
Read Our Latest Stock Report on ACLX
About Arcellx
(
Get Free Report)
Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
